• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

季节性流感疫苗免疫后对同源和变异甲型流感病毒的神经氨酸酶抗体反应

Neuraminidase Antibody Response to Homologous and Drifted Influenza A Viruses After Immunization with Seasonal Influenza Vaccines.

作者信息

Desheva Yulia, Sergeeva Maria, Kudar Polina, Rekstin Andrey, Romanovskaya-Romanko Ekaterina, Krivitskaya Vera, Kudria Kira, Bazhenova Ekaterina, Stepanova Ekaterina, Krylova Evelina, Kurpiaeva Maria, Lioznov Dmitry, Stukova Marina, Kiseleva Irina

机构信息

FSBSI 'Institute of Experimental Medicine', 197022 Saint Petersburg, Russia.

Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, 197022 Saint Petersburg, Russia.

出版信息

Vaccines (Basel). 2024 Nov 27;12(12):1334. doi: 10.3390/vaccines12121334.

DOI:10.3390/vaccines12121334
PMID:39771996
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11680112/
Abstract

BACKGROUND/OBJECTIVES: Humoral immunity directed against neuraminidase (NA) of the influenza virus may soften the severity of infection caused by new antigenic variants of the influenza viruses. Evaluation of NA-inhibiting (NI) antibodies in combination with antibodies to hemagglutinin (HA) may enhance research on the antibody response to influenza vaccines.

METHODS

The study examined 64 pairs of serum samples from patients vaccinated with seasonal inactivated trivalent influenza vaccines (IIVs) in 2018 according to the formula recommended by the World Health Organization (WHO) for the 2018-2019 flu season. Antibodies against drift influenza viruses A/Guangdong-Maonan/SWL1536/2019(H1N1)pdm09 and A/Brisbane/34/2018(H3N2) were studied before vaccination and 21 days after vaccination. To assess NI antibodies, we used an enzyme-linked lectin assay (ELLA) with pairs of reassortant viruses A/H6N1 and A/H6N2. Anti-HA antibodies were detected using a hemagglutination inhibition (HI) test. The microneutralization (MN) test was performed in the MDCK cell line using viruses A/H6N1 and A/H6N2.

RESULTS

Seasonal IIVs induce a significant immune response of NI antibodies against influenza A/H1N1pdm09 and A/H3N2 viruses. A significantly reduced 'herd' immunity to drift influenza A/H1N1pdm09 and A/H3N2 viruses was shown, compared with previously circulating strains. This reduction was most pronounced in strains possessing neuraminidase N2. Seasonal IIVs caused an increase in antibodies against homologous and drifted viruses; however, an increase in antibodies to drifting viruses was observed more often among older patients. The level of NI antibodies for later A/H1N1pdm09 virus in response to IIVs was statistically significantly lower among younger people. After IIV vaccination, the percentage of individuals with HI antibody levels ≥ 1:40 and NI antibody levels ≥ 1:20 was 32.8% for drift A/H1N1pdm09 virus and 17.2% for drift A/H3N2 virus. Antisera containing HI and NI antibodies exhibited neutralizing properties in vitro against viruses with unrelated HA of the H6 subtype.

CONCLUSIONS

Drift A/H1N1pdm09 and A/H3N2 viruses demonstrated significantly lower reactivity to HI and NI antibodies against early influenza viruses. In response to seasonal IIVs, the level of seroprotection has increased, including against drift influenza A viruses, but protective antibody levels against A/H1N1pdm09 have risen to a greater extent. A reduced immune response to the N1 protein of the A/H1N1pdm09 drift virus was obtained in individuals under 60 years of age. Based on our findings, it is hypothesized that in the cases of a HA mismatch, vaccination against N1-containing influenza viruses may be necessary for individuals under 60, while broader population-level vaccination against N2-containing viruses may be required.

摘要

背景/目的:针对流感病毒神经氨酸酶(NA)的体液免疫可能会减轻由流感病毒新抗原变体引起的感染严重程度。评估NA抑制(NI)抗体与血凝素(HA)抗体相结合,可能会加强对流感疫苗抗体反应的研究。

方法

该研究根据世界卫生组织(WHO)针对2018 - 2019流感季节推荐的公式,检测了2018年接种季节性三价灭活流感疫苗(IIV)的64对患者血清样本。在接种疫苗前和接种疫苗21天后,研究了针对漂移流感病毒A/广东 - 茂南/SWL1536/2019(H1N1)pdm09和A/布里斯班/34/2018(H3N2)的抗体。为了评估NI抗体,我们使用了重组病毒A/H6N1和A/H6N2对的酶联凝集试验(ELLA)。使用血凝抑制(HI)试验检测抗HA抗体。在MDCK细胞系中使用病毒A/H6N1和A/H6N2进行微量中和(MN)试验。

结果

季节性IIV可诱导针对甲型流感H1N1pdm09和H3N2病毒的NI抗体产生显著免疫反应。与先前流行的毒株相比,对漂移甲型流感H1N1pdm09和H3N2病毒的“群体”免疫力显著降低。这种降低在具有神经氨酸酶N2的毒株中最为明显。季节性IIV导致针对同源和漂移病毒的抗体增加;然而,在老年患者中更常观察到针对漂移病毒的抗体增加。在年轻人中,针对后期甲型流感H1N1pdm09病毒的NI抗体水平在统计学上显著低于老年人。接种IIV后,HI抗体水平≥1:40且NI抗体水平≥1:20的个体百分比,对于漂移甲型流感H1N1pdm09病毒为32.8%,对于漂移甲型流感H3N2病毒为17.2%。含有HI和NI抗体的抗血清在体外对具有H6亚型不相关HA的病毒具有中和特性。

结论

漂移甲型流感H1N1pdm09和H3N2病毒对针对早期流感病毒的HI和NI抗体反应显著降低。针对季节性IIV,血清保护水平有所提高,包括针对漂移甲型流感病毒,但针对甲型流感H1N1pdm09的保护性抗体水平上升幅度更大。60岁以下个体对甲型流感H1N1pdm09漂移病毒的N1蛋白免疫反应降低。根据我们的研究结果,推测在HA不匹配的情况下,60岁以下个体可能需要接种针对含N1流感病毒的疫苗,而可能需要对更广泛的人群接种针对含N2病毒的疫苗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eaa/11680112/d7ef5677e1d9/vaccines-12-01334-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eaa/11680112/662a4718fc9f/vaccines-12-01334-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eaa/11680112/e721b72b592d/vaccines-12-01334-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eaa/11680112/396506e777ac/vaccines-12-01334-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eaa/11680112/e52cdcd63086/vaccines-12-01334-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eaa/11680112/ce92b8b17de8/vaccines-12-01334-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eaa/11680112/1e7e602976e9/vaccines-12-01334-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eaa/11680112/d7ef5677e1d9/vaccines-12-01334-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eaa/11680112/662a4718fc9f/vaccines-12-01334-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eaa/11680112/e721b72b592d/vaccines-12-01334-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eaa/11680112/396506e777ac/vaccines-12-01334-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eaa/11680112/e52cdcd63086/vaccines-12-01334-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eaa/11680112/ce92b8b17de8/vaccines-12-01334-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eaa/11680112/1e7e602976e9/vaccines-12-01334-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8eaa/11680112/d7ef5677e1d9/vaccines-12-01334-g007.jpg

相似文献

1
Neuraminidase Antibody Response to Homologous and Drifted Influenza A Viruses After Immunization with Seasonal Influenza Vaccines.季节性流感疫苗免疫后对同源和变异甲型流感病毒的神经氨酸酶抗体反应
Vaccines (Basel). 2024 Nov 27;12(12):1334. doi: 10.3390/vaccines12121334.
2
Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.健康志愿者体内针对大流行的A/加利福尼亚/07/2009(H1N1)流感病毒的血清型特异性或交叉反应性神经氨酸酶抑制抗体。
BMC Res Notes. 2015 Apr 10;8:136. doi: 10.1186/s13104-015-1086-z.
3
Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.灭活H7流感病毒疫苗尽管仅诱导产生低水平的中和抗体,但仍可保护小鼠。
J Virol. 2017 Sep 27;91(20). doi: 10.1128/JVI.01202-17. Print 2017 Oct 15.
4
Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies.甲型 H1N1 流感病毒神经氨酸酶抗原漂移导致 A/加利福尼亚/7/2009(H1N1pdm09)特异性抗体效力降低。
mBio. 2019 Apr 9;10(2):e00307-19. doi: 10.1128/mBio.00307-19.
5
Imprinted Anti-Hemagglutinin and Anti-Neuraminidase Antibody Responses after Childhood Infections of A(H1N1) and A(H1N1)pdm09 Influenza Viruses.儿童感染 A(H1N1)和 A(H1N1)pdm09 流感病毒后的抗血凝素和抗神经氨酸酶抗体反应。
mBio. 2023 Jun 27;14(3):e0008423. doi: 10.1128/mbio.00084-23. Epub 2023 Apr 18.
6
Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United States.抗原漂移和亚型干扰塑造了美国 A(H3N2) 流感的流行动态。
Elife. 2024 Sep 25;13:RP91849. doi: 10.7554/eLife.91849.
7
Anti-neuraminidase antibodies against pandemic A/H1N1 influenza viruses in healthy and influenza-infected individuals.针对健康人群和流感感染人群的大流行性 A/H1N1 流感病毒的神经氨酸酶抗体。
PLoS One. 2018 May 9;13(5):e0196771. doi: 10.1371/journal.pone.0196771. eCollection 2018.
8
Longitudinal Analysis of Neuraminidase and Hemagglutinin Antibodies to Influenza A Viruses after Immunization with Seasonal Inactivated Influenza Vaccines.季节性灭活流感疫苗免疫后甲型流感病毒神经氨酸酶和血凝素抗体的纵向分析
Vaccines (Basel). 2023 Nov 20;11(11):1731. doi: 10.3390/vaccines11111731.
9
Study of Neuraminidase-Inhibiting Antibodies in Clinical Trials of Live Influenza Vaccines.活流感疫苗临床试验中神经氨酸酶抑制抗体的研究
Antibodies (Basel). 2020 May 29;9(2):20. doi: 10.3390/antib9020020.
10
Highly Cross-Reactive and Protective Influenza A Virus H3N2 Hemagglutinin- and Neuraminidase-Specific Human Monoclonal Antibodies.高度交叉反应性和保护性的流感 A 病毒 H3N2 血凝素和神经氨酸酶特异性人源单克隆抗体。
Microbiol Spectr. 2023 Aug 17;11(4):e0472822. doi: 10.1128/spectrum.04728-22. Epub 2023 Jun 15.

引用本文的文献

1
Incidence of Circulating Antibodies Against Hemagglutinin of Influenza Viruses in Epidemic Season 2023/2024 in Poland.2023/2024流行季节波兰针对流感病毒血凝素的循环抗体发生率
Biomolecules. 2025 Jul 7;15(7):977. doi: 10.3390/biom15070977.
2
The global burden of swine influenza and its mitigation.猪流感的全球负担及其缓解措施。
Open Vet J. 2025 May;15(5):1866-1879. doi: 10.5455/OVJ.2025.v15.i5.3. Epub 2025 May 31.

本文引用的文献

1
Longitudinal assessment of human antibody binding to hemagglutinin elicited by split-inactivated influenza vaccination over six consecutive seasons.连续六个流感季节中,评估人针对裂解型流感疫苗诱导产生的血凝素的抗体结合情况的纵向研究。
PLoS One. 2024 Jun 25;19(6):e0301157. doi: 10.1371/journal.pone.0301157. eCollection 2024.
2
Longitudinal Analysis of Neuraminidase and Hemagglutinin Antibodies to Influenza A Viruses after Immunization with Seasonal Inactivated Influenza Vaccines.季节性灭活流感疫苗免疫后甲型流感病毒神经氨酸酶和血凝素抗体的纵向分析
Vaccines (Basel). 2023 Nov 20;11(11):1731. doi: 10.3390/vaccines11111731.
3
Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidase.
利用疫苗诱导的保护性抗体来确定流感 N2 神经氨酸酶上的保守表位。
Immunity. 2023 Nov 14;56(11):2621-2634.e6. doi: 10.1016/j.immuni.2023.10.005.
4
Seasonal Influenza Vaccine Effectiveness in Persons Aged 15-64 Years: A Systematic Review and Meta-Analysis.15至64岁人群中季节性流感疫苗的有效性:一项系统评价与荟萃分析
Vaccines (Basel). 2023 Aug 4;11(8):1322. doi: 10.3390/vaccines11081322.
5
Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo.大流行 H1N1 病毒感染诱导的人抗 N1 单克隆抗体在体外和体内广泛抑制 HxN1 病毒。
Immunity. 2023 Aug 8;56(8):1927-1938.e8. doi: 10.1016/j.immuni.2023.07.004. Epub 2023 Jul 27.
6
Factors affecting the immunogenicity of influenza vaccines in human.影响流感疫苗在人体中免疫原性的因素。
BMC Infect Dis. 2023 Apr 6;23(1):211. doi: 10.1186/s12879-023-08158-3.
7
Determining Existing Human Population Immunity as Part of Assessing Influenza Pandemic Risk.评估流感大流行风险的一部分是确定现有人群的免疫情况。
Emerg Infect Dis. 2022 May;28(5):977-985. doi: 10.3201/eid2805.211965.
8
Antigenic Drift of the Hemagglutinin from an Influenza A (H1N1) pdm09 Clinical Isolate Increases its Pathogenicity In Vitro.甲型流感病毒(H1N1)pdm09 临床分离株血凝素抗原漂移增加其体外致病性。
Virol Sin. 2021 Oct;36(5):1220-1227. doi: 10.1007/s12250-021-00401-y. Epub 2021 Jun 9.
9
Low-dose influenza vaccine Grippol Quadrivalent with adjuvant Polyoxidonium induces a T helper-2 mediated humoral immune response and increases NK cell activity.含佐剂 Polyoxidonium 的低剂量流感疫苗 Grippol 四价疫苗可诱导辅助性 T 细胞 2 介导的体液免疫应答,并增加 NK 细胞活性。
Vaccine. 2020 Sep 29;38(42):6645-6655. doi: 10.1016/j.vaccine.2020.07.053. Epub 2020 Aug 29.
10
Human germinal centres engage memory and naive B cells after influenza vaccination.人类生发中心在流感疫苗接种后会募集记忆 B 细胞和初始 B 细胞。
Nature. 2020 Oct;586(7827):127-132. doi: 10.1038/s41586-020-2711-0. Epub 2020 Aug 31.